NCT07865520Completed
Alcohol Consumption and Plasma cfDNA Methylation in Chronic Hepatitis B
A Preliminary Exploration of the Effect of Alcohol Consumption on Plasma Cell-Free DNA Methylation Profiles in Participants With Chronic Hepatitis B
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
This is an observational, exploratory study designed to investigate the effect of different levels of alcohol consumption on plasma cell-free DNA (cfDNA) methylation profiles in participants with chronic hepatitis B. A total of 85 participants with chronic hepatitis B are planned to be enrolled and grouped according to their alcohol consumption status into a non-drinking group, a drinking group, and a group with alcoholic hepatitis associated with alcohol consumption. Approximately 16 mL of peripheral blood will be collected from each participant for cfDNA methylation analysis. Plasma cfDNA methylation profiles will be compared among participants with different levels of alcohol consumption to explore the effects of alcohol consumption on cfDNA methylation.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 85 (actual)
- First submitted
- 3 Oct 2026
- Start date
- 21 Nov 2025
- Primary completion date
- 31 May 2026
- Lead sponsor
- Beijing Municipal Administration of Hospitals
- Diseases
- Hepatitis B
- NCT number
- NCT07865520
What you commit to
- Study type: Observational
- Participants enrolled: 85
- From 21 Nov 2025 to the primary completion date, 31 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of severe acute infectious disease within 14 days before screening, such as severe or critical COVID-19 or sepsis.
- Use of any of the following medications within 14 days before screening: intravenous or oral glucocorticoids; intravenous or oral azacitidine, decitabine, procainamide, hydralazine, or arsenic trioxide.
- Previous organ transplantation, bone marrow transplantation, or stem cell transplantation, or blood transfusion within 30 days before screening.
Other illness
- History of cancer or presence of cancer at screening.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study.
Other
- Liver cirrhosis.
- Pregnant or breastfeeding women.
Who the study is looking for
- Age ≥30 years and \<75 years.
- Diagnosed with chronic hepatitis B.
- Able and willing to provide written informed consent and comply with study sampling and assessments.
Age in the registry: 30 years to 74 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Ditan Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.